|
1
|
Matsuda T, Marugame T, Kamo K, Katanoda K,
Ajiki W and Sobue T; Japan Cancer Surveillance Research Group.
Cancer incidence and incidence rates in Japan in 2005: based on
data from 12 population-based cancer registries in the Monitoring
of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol.
41:139–147. 2011. View Article : Google Scholar
|
|
2
|
Parker JS, Mullins M, Cheang MC, et al:
Supervised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van’t Veer LJ, Dai H, van de Vijver MJ, et
al: Gene expression profiling predicts clinical outcome of breast
cancer. Nature. 415:530–536. 2002. View
Article : Google Scholar
|
|
4
|
Cronin M, Sangli C, Liu ML, Pho M, Dutta
D, Nguyen A, Jeong J, Wu J, Langone KC and Watson D: Analytical
validation of the Oncotype DX genomic diagnostic test for
recurrence prognosis and therapeutic response prediction in
node-negative, estrogen receptor-positive breast cancer. Clin Chem.
53:1084–1091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sierra JR and Tsao MS: c-MET as a
potential therapeutic target and biomarker in cancer. Ther Adv Med
Oncol. 3(Suppl 1): S21–S35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Turner N, Lambros MB, Horlings HM, et al:
Integrative molecular profiling of triple negative breast cancers
identifies amplicon drivers and potential therapeutic targets.
Oncogene. 29:2013–2023. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Turner N, Tutt A and Ashworth A: Hallmarks
of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stein U, Walther W, Arlt F, Schwabe H,
Smith J, Fichtner I, Birchmeier W and Schlag PM: MACC1, a newly
identified key regulator of HGF-MET signaling, predicts colon
cancer metastasis. Nat Med. 15:59–67. 2009. View Article : Google Scholar
|
|
9
|
Boardman LA: Overexpression of MACC1 leads
to downstream activation of HGF/MET and potentiates metastasis and
recurrence of colorectal cancer. Genome Med. 1:362009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C,
Wang L, Wang J and Yuan Y: Identification of MACC1 as a novel
prognostic marker in hepatocellular carcinoma. J Transl Med.
9:1662011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Wu Y, Lin L, et al:
Metastasis-associated in colon cancer-1 upregulation predicts a
poor prognosis of gastric cancer, and promotes tumor cell
proliferation and invasion. Int J Cancer. 133:1419–1430. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang R, Shi H, Chen Z, Wu Q, Ren F and
Huang H: Effects of metastasis-associated in colon cancer 1
inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells.
J Exp Clin Cancer Res. 30:832011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maulik G, Shrikhande A, Kijima T, Ma PC,
Morrison PT and Salgia R: Role of the hepatocyte growth factor
receptor, c-Met, in oncogenesis and potential for therapeutic
inhibition. Cytokine Growth Factor Rev. 13:41–59. 2002. View Article : Google Scholar
|
|
14
|
Bottaro DP, Rubin JS, Faletto DL, Chan AM,
Kmiecik TE, Vande Woude GF and Aaronson SA: Identification of the
hepatocyte growth factor receptor as the c-met proto-oncogene
product. Science. 251:802–804. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Di Renzo MF, Olivero M, Giacomini A, et
al: Overexpression and amplification of the met/HGF receptor gene
during the progression of colorectal cancer. Clin Cancer Res.
1:147–154. 1995.PubMed/NCBI
|
|
16
|
Humphrey PA, Zhu X, Zarnegar R, Swanson
PE, Ratliff TL, Vollmer RT and Day ML: Hepatocyte growth factor and
its receptor (c-MET) in prostatic carcinoma. Am J Pathol.
147:386–396. 1995.PubMed/NCBI
|
|
17
|
Amemiya H, Kono K, Itakura J, Tang RF,
Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H and Matsumoto Y:
c-Met expression in gastric cancer with liver metastasis. Oncology.
63:286–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph
A, Lamszus K, Park M, Goldberg ID and Rosen EM: Expression of
scatter factor and c-met receptor in benign and malignant breast
tissue. Cancer. 79:749–760. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Camp RL, Rimm EB and Rimm DL: Met
expression is associated with poor outcome in patients with
axillary lymph node negative breast carcinoma. Cancer.
86:2259–2265. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lengyel E, Prechtel D, Resau JH, et al:
C-Met overexpression in node-positive breast cancer identifies
patients with poor clinical outcome independent of Her2/neu. Int J
Cancer. 113:678–682. 2005. View Article : Google Scholar
|
|
21
|
Stein U, Smith J, Walther W and Arlt F:
MACC1 controls Met: what a difference an Sp1 site makes. Cell
Cycle. 8:2467–2469. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members. Strategies for
subtypes - dealing with the diversity of breast cancer: highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamamoto S, Ibusuki M, Yamamoto Y, Fu P,
Fujiwara S, Murakami K and Iwase H: Clinical relevance of Ki67 gene
expression analysis using formalin-fixed paraffin-embedded breast
cancer specimens. Breast Cancer. 20:262–270. 2013. View Article : Google Scholar
|
|
24
|
Dowsett M, Nielsen TO, A’Hern R, et al;
International Ki-67 in Breast Cancer Working Group. Assessment of
Ki67 in breast cancer: recommendations from the International Ki67
in Breast Cancer working group. J Natl Cancer Inst. 103:1656–1664.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hartzell DD, Trinklein ND, Mendez J,
Murphy N, Aldred SF, Wood K and Urh M: A functional analysis of the
CREB signaling pathway using HaloCHIP-chip and high throughput
reporter assays. BMC Genomics. 10:4972009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye
C, Zhu X and Li M: Overexpression of MACC1 and its significance in
human breast cancer progression. Cell Biosci. 3:162013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Law JH, Habibi G, Hu K, et al:
Phosphorylated insulin-like growth factor-i/insulin receptor is
present in all breast cancer subtypes and is related to poor
survival. Cancer Res. 68:10238–10246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Railo MJ, von Smitten K and Pekonen F: The
prognostic value of insulin-like growth factor-I in breast cancer
patients. Results of a follow-up study on 126 patients. Eur J
Cancer. 30A:307–311. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin A, Ren Z, Shu XO, Cai Q, Gao YT and
Zheng W: Expression patterns of insulin-like growth factor 1
(IGF-I) and its receptor in mammary tissues and their associations
with breast cancer survival. Breast Cancer Res Treat. 105:55–61.
2007. View Article : Google Scholar
|
|
30
|
Papa V, Gliozzo B, Clark GM, McGuire WL,
Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID and Pezzino V:
Insulin-like growth factor-I receptors are overexpressed and
predict a low risk in human breast cancer. Cancer Res.
53:3736–3740. 1993.PubMed/NCBI
|
|
31
|
Stein U, Dahlmann M and Walther W: MACC1 -
more than metastasis? Facts and predictions about a novel gene. J
Mol Med Berl. 88:11–18. 2010. View Article : Google Scholar
|
|
32
|
|
|
33
|
Kang JY, Dolled-Filhart M, Ocal IT, Singh
B, Lin CY, Dickson RB, Rimm DL and Camp RL: Tissue microarray
analysis of hepatocyte growth factor/Met pathway components reveals
a role for Met, matriptase, and hepatocyte growth factor activator
inhibitor 1 in the progression of node-negative breast cancer.
Cancer Res. 63:1101–1105. 2003.PubMed/NCBI
|
|
34
|
Boccaccio C and Comoglio PM: Invasive
growth: A MET-driven genetic programme for cancer and stem cells.
Nat Rev Cancer. 6:637–645. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peschard P and Park M: From Tpr-Met to
Met, tumorigenesis and tubes. Oncogene. 26:1276–1285. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Trusolino L, Bertotti A and Comoglio PM:
MET signalling: Principles and functions in development, organ
regeneration and cancer. Nat Rev Mol Cell Biol. 11:834–848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ghoussoub RA, Dillon DA, D’Aquila T, Rimm
EB, Fearon ER and Rimm DL: Expression of c-met is a strong
independent prognostic factor in breast carcinoma. Cancer.
82:1513–1520. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hiscox S, Jordan NJ, Jiang W, Harper M,
McClelland R, Smith C and Nicholson RI: Chronic exposure to
fulvestrant promotes overexpression of the c-Met receptor in breast
cancer cells: Implications for tumour-stroma interactions. Endocr
Relat Cancer. 13:1085–1099. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shattuck DL, Miller JK, Carraway KL III
and Sweeney C: Met receptor contributes to trastuzumab resistance
of Her2-over-expressing breast cancer cells. Cancer Res.
68:1471–1477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Minuti G, Cappuzzo F, Duchnowska R, et al:
Increased MET and HGF gene copy numbers are associated with
trastuzumab failure in HER2-positive metastatic breast cancer. Br J
Cancer. 107:793–799. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiang WG, Martin TA, Parr C, Davies G,
Matsumoto K and Nakamura T: Hepatocyte growth factor, its receptor,
and their potential value in cancer therapies. Crit Rev Oncol
Hematol. 53:35–69. 2005. View Article : Google Scholar
|
|
42
|
Maemura M, Iino Y, Yokoe T, Horiguchi J,
Takei H, Koibuchi Y, Horii Y, Takeyoshi I, Ohwada S and Morishita
Y: Serum concentration of hepatocyte growth factor in patients with
metastatic breast cancer. Cancer Lett. 126:215–220. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Arlt F and Stein U: Colon cancer
metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem
Cell Biol. 41:2356–2359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pennacchietti S, Michieli P, Galluzzo M,
Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive
growth by transcriptional activation of the met protooncogene.
Cancer Cell. 3:347–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ipsaro JJ, Huang L and Mondragón A:
Structures of the spectrin-ankyrin interaction binding domains.
Blood. 113:5385–5393. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kadonaga JT, Jones KA and Tjian R:
Promoter-specific activation of RNA polymerase II transcription by
Sp1. Trends Biochem Sci. 11:20–23. 1986. View Article : Google Scholar
|
